GliXogen Therapeutics Overview
- Year Founded
-
2018
- Status
-
Out of Business
- Employees
-
2
- Latest Deal Type
-
Out of Business
GliXogen Therapeutics General Information
Description
Developer of a novel therapy designed to reverse the course of demyelination disorders. The company engages in the development of a treatment to enhance remyelination in neurodegenerative disorders that are driven by damage to the neuron's myelin sheath, such as multiple sclerosis, enabling patients to have easier and better treatment for the disease.
Contact Information
Website
www.glixogen.comCorporate Office
- 2 Ilan Ramon
- Ness Ziona 7403635
- Israel
Corporate Office
- 2 Ilan Ramon
- Ness Ziona 7403635
- Israel
GliXogen Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Out of Business | 01-Dec-2024 | Completed | Out of Business | |||
| 2. Early Stage VC | 22-Jun-2022 | Completed | Startup | |||
| 1. Accelerator/Incubator | 14-Jan-2019 | $3M | $3M | Completed | Startup |
GliXogen Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preference |
GliXogen Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
GliXogen Therapeutics Patents
GliXogen Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230242511-A1 | Fused pyrazole and imidazole based compounds and use thereof as gli1 inhibitors | Inactive | 14-May-2020 | ||
| WO-2021229583-A1 | Fused pyrazole and imidazole based compounds and use thereof as gli1 inhibitors | Inactive | 14-May-2020 |
GliXogen Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
GliXogen Therapeutics FAQs
-
When was GliXogen Therapeutics founded?
GliXogen Therapeutics was founded in 2018.
-
Where is GliXogen Therapeutics headquartered?
GliXogen Therapeutics is headquartered in Ness Ziona, Israel.
-
What is the size of GliXogen Therapeutics?
GliXogen Therapeutics has 2 total employees.
-
What industry is GliXogen Therapeutics in?
GliXogen Therapeutics’s primary industry is Drug Discovery.
-
Is GliXogen Therapeutics a private or public company?
GliXogen Therapeutics is a Private company.
-
What is GliXogen Therapeutics’s current revenue?
The current revenue for GliXogen Therapeutics is .
-
How much funding has GliXogen Therapeutics raised over time?
GliXogen Therapeutics has raised $4.5M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
